To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?

2025/05/06 by Laurence Ollier, Anne De Monte, Vincent Thibault +5 · 1 voice · 1 citation
Medicine · #Hepatitis B Virus Studies #Hepatitis C virus research #Liver Disease Diagnosis and Treatment

paper · pdf · doi:10.1093/ofid/ofaf266

openalex created_date 2025/05/06 · openalex publication_date 2025/05/06 · openalex updated_date 2026/07/30

Abstract

We report the occurrence of low-level hepatitis B virus (HBV) viremia in people with HIV with controlled CD4 counts and isolated core antibody reactivity switched to long-acting injectable cabotegravir/rilpivirine. This series raises questions about the reintroduction of anti-HBV medications, presents the variation of several HBV markers alongside HBV-DNA and reveals an effective spontaneous immune response.

Cited by

• Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years

Discussions

• To switch or not to switch to long-acting injectable cabotegravir/rilpivirine in PLWH with past hepatitis B virus coinfection: which HBV markers to manage risk of HBV reactivation? ✅ Just Accepted #I [bsky, 9 points, 0 comments]

Related

• Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice
• Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
• Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy
• High titers of anti‐HBs prevent rituximab‐related viral reactivation in resolved hepatitis B patient with non‐Hodgkin's lymphoma
• Hepatitis B virus reactivation during cytotoxic chemotherapy‐enhanced viral replication precedes overt hepatitis